Methods of treating cholangiocarcinoma
Provided herein are methods of treating advanced or metastatic cholangiocarcinoma in a patient by administering to the patient infigratinib or a pharmaceutically acceptable salt thereof, wherein the patient has progression of the cholangiocarcinoma after previous administration of another therapy.
1. A method for treating advanced or metastatic cholangiocarcinoma in a subject in need thereof, comprising:
administering infigratinib monophosphate salt once daily in an amount of about 50, 75, 100, or 125 milligrams (mg) by weight in its free base form,
wherein the subject has progression of the cholangiocarcinoma after previous administration of another therapy; the cholangiocarcinoma has an FGFR2 gene fusion, translocation, or another genetic alteration; the about 125 mg amount of infigratinib monophosphate salt is provided as a 100 mg unit dose and a 25 mg unit dose, each by weight in its free base form; the infigratinib monophosphate salt is administered at least 1 hour before the subject consumes food or at least 2 hours after the subject has consumed food; and administering the infigratinib monophosphate salt comprises a 28-day cycle in which the infigratinib monophosphate salt is administered to the subject for 3 consecutive weeks, and no infigratinib monophosphate salt is administered for 1 week.
2. The method of claim 1 , wherein the previous administration of another therapy is a therapy for advanced or metastatic cholangiocarcinoma.
3. The method of claim 1 , wherein the previous administration of another therapy is an administration of a chemotherapeutic agent.
4. The method of claim 3 , wherein the previous administration of a chemotherapeutic agent is a gemcitabine-containing regimen.
5. The method of claim 1 , wherein the cholangiocarcinoma has a FGFR1 and/or a FGFR3 gene fusion, translocation, or other genetic alteration.
6. The method of claim 1 , wherein the FGFR2 gene fusion comprises a FGFR2 gene fusion partner selected from the group consisting of 10Q26.13, AFF1, AFF4, AHCYL1, ALDHIL2, ARFIP1, BICC1, C10orf118, C7, CCDC147, CCDC6, CELF2, CREB5, CREM, DNAJC12, HOOK1, KCTD1, KIAA1217, KIAA1598, KIFC3, MGEA5, NOL4, NRAP, OPTN, PARK2, PAWR, PCMI, PHLDB2, PPHLN1, RASAL2, SFMBT2, SLMAP, SLMAP2, SORBS1, STK26, STK3, TACC3, TBC1D1, TFEC, TRA2B, UBQLN1, VCL, WAC, and ZMYM4.
7. The method of claim 1 , wherein the advanced or metastatic cholangiocarcinoma is histologically or cytologically confirmed.
8. The method of claim 1 , wherein the cholangiocarcinoma has a FGFR1, a FGFR2 and/or a FGFR3 mutation.
9. The method of claim 8 , wherein the FGFR1, FGFR2, and/or FGFR3 mutation is selected from the group consisting of FGFR1 G818R, FGFR1 K656E, FGFR1 N546K, FGFR1 R445W, FGFR1 T141R, FGFR2 A315T, FGFR2 C382R, FGFR2 D336N, FGFR2 D471N, FGFR2 E565A, FGFR2 1547V, FGFR2 K641R, FGFR2 K659E, FGFR2 K659M, FGFR2 L617V, FGFR2 N549H, FGFR2 N549K, FGFR2 N549S, FGFR2 N549Y, FGFR2 N550K, FGFR2 P253R, FGFR2 S252W, FGFR2 V395D, FGFR2 V564F, FGFR2 Y375C, FGFR3 A391E, FGFR3 D785Y, FGFR3 E627K, FGFR3 G370C, FGFR3 G380R, FGFR3 K650E, FGFR3 K650M, FGFR3 K650N, FGFR3 K650T, FGFR3 K652E, FGFR3 N540S, FGFR3R248C, FGFR3 R399C, FGFR3 S131L, FGFR3 S249C, FGFR3 S371C, FGFR3 V555M, FGFR3 V677I, FGFR3 Y373C, FGFR4 D425N, FGFR4 R183S, FGFR4R394Q, FGFR4 R610H, FGFR4 V510L, and a combination thereof.
10. The method of claim 1 , wherein the cholangiocarcinoma has amplification of FGFR1, FGFR2, and/or FGFR3.
11. The method of claim 1 , wherein the previous administration of another therapy is administration of a receptor tyrosine kinase inhibitor.
12. The method of claim 11 , wherein the receptor tyrosine kinase inhibitor is a selective inhibitor of FGFR1, FGFR2, FGFR3, and/or FGFR4.
13. The method of claim 12 , wherein the selective inhibitor of FGFR1, FGFR2, FGFR3, and/or FGFR4 is selected from the group consisting of pemigatinib, rogaratinib, derazantinib, Debio1347, AZD4547, erdafitinib, LY2874455, PRN 1371, ASP5878, TAS120, and a combination thereof.
14. The method of claim 11 , wherein the receptor tyrosine kinase inhibitor is a non-selective tyrosine kinase inhibitor.
15. The method of claim 14 , wherein the non-selective tyrosine kinase inhibitor is selected from the group consisting of ponatinib, dovitinib, levatanib, ACTB-1003, Ki8751, lucitinib, masitinib, mubritinib, nintedanib, orantinib, PD089828, and a combination thereof.
16. The method of claim 1 , wherein the about 100 mg of infigratinib monophosphate salt is provided as a 100 mg unit dose, by weight in its free base form.
17. The method of claim 1 , wherein the about 50 mg of infigratinib monophosphate salt is provided as two 25 mg unit doses, each by weight in its free base form.